Vor Bio (VOR) announced the dosing of the first patient in UPSTREAM SjD, a global, randomized, double-blind, placebo-controlled Phase 3 trial evaluating telitacicept in adult patients with active primary Sjogren’s disease, formerly known as Sjogren’s syndrome.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VOR:
- Vor Bio initiated with a Buy at Jefferies
- Vor Biopharma: Strategic Autoimmune Pivot and Telitacicept’s >$2B gMG/SjD Opportunity Underpins Buy Rating
- Vor Biopharma Announces $75 Million Private Placement Financing
- Vor Bio to sell 5.338M shares at $14.05 in private placement
- Vor Bio initiated with an Overweight at Wells Fargo